PD-1/PD-L1
Les inhibiteurs de PD-1/PD-L1 sont des inhibiteurs de points de contrôle immunitaires qui bloquent l'interaction entre la protéine de mort cellulaire programmée 1 (PD-1) sur les cellules T et son ligand PD-L1 sur les cellules cancéreuses. Cette interaction supprime normalement la réponse immunitaire et permet aux cellules cancéreuses d'échapper à la détection immunitaire. En inhibant PD-1/PD-L1, ces inhibiteurs renforcent la capacité du système immunitaire à reconnaître et à détruire les cellules cancéreuses, induisant l'apoptose et la régression tumorale. Les inhibiteurs de PD-1/PD-L1 sont essentiels dans la recherche en immunothérapie et dans le traitement du cancer. Chez CymitQuimica, nous offrons une gamme d'inhibiteurs de PD-1/PD-L1 de haute qualité pour soutenir vos recherches en immuno-oncologie, apoptose et thérapie contre le cancer.
140 produits trouvés pour "PD-1/PD-L1"
Trier par
Degré de pureté (%)
0
100
|
0
|
50
|
90
|
95
|
100
Volrustomig
CAS :Volrustomig is a bi-engineered fragment crystallizable (Fc) domain, a monovalent bispecific IgG1 monoclonal antibody targeting the key immune checkpoint receptors PD-1 and CTLA-4. It boosts T-cell activation and antitumor immunity, making it a promising immunotherapy for various cancers. Molecular weight: 146.77 kDa.Couleur et forme :LiquidNofazinlimab
CAS :Nofazinlimab (CS1003) is a human anti-PD-1 IgG4 monoclonal antibody for the study of unresectable hepatocellular carcinoma (uHCC).Degré de pureté :98.6% (SDS-PAGE); 99.7% (SEC-HPLC) - 98.6% (SDS-PAGE); 99.7% (SEC-HPLC)Couleur et forme :LiquidMasse moléculaire :145.07 kDaSudubrilimab
Sudubrilimab (HS636) is an IgG1-κ monoclonal antibody targeting PDL1, fused with TGFBR2-ECD to block PD-1/PDL1 and TGF-β in tumors.Couleur et forme :Odour LiquidBetifisolimab
CAS :Betifisolimab (MSB-2311) is a humanized antibody targeting PD-L1 for solid tumors and blood cancer research.Couleur et forme :LiquidSasanlimab
CAS :Sasanlimab (PF-06801591), a humanized IgG4-κ antibody, selectively targets PD-1 and is primarily produced in Chinese Hamster Ovary (CHO) cells [1].Degré de pureté :98%Couleur et forme :LiquidPimivalimab
CAS :Pimivalimab (JTX-4014), a PD-1 inhibitor, is utilized in solid tumor research [1].Couleur et forme :LiquidLedostomig
CAS :Ledostomig is an immunoglobulin (H-γ1-scFv-L-κ) dimer monoclonal antibody that targets human neurotensin receptor type 5 (NTS5) and programmed death-1 (PD-1). It shows potential for research in various cancer types.Couleur et forme :LiquidAnti-Mouse PD-1 Antibody (29F.1A12)
The Anti-MousePD-1Antibody (29F.1A12) is an antibody derived from rat IgG2akappa that targets PD-1 in mice. The isotype control for Anti-MousePD-1Antibody (29F.1A12) is RatIgG2akappa, Isotype Control.Masse moléculaire :150 kDa2-Methylbiphenyl-oxadiazole-NH-Ph-CHO
CAS :2-Methylbiphenyl-oxadiazole-NH-Ph-CHO functions as a PD-L1 ligand for AUTACPD-L1degrader-3. It is also applicable in the synthesis of AUTAC.Formule :C22H17N3O2Couleur et forme :SolidMasse moléculaire :355.392-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc
2-Methylbiphenyl-oxadiazole-NH-Ph-NH-PEG3-C2-NH-Boc is the PD-L1 ligand-linker polymer of AUTACPD-L1degrader-3. It can be utilized in the synthesis of AUTAC.Formule :C35H45N5O6Couleur et forme :SolidMasse moléculaire :631.76LTB
LTB is a prodrug formed through the conjugation of the glycolysis inhibitor (Lonidamine) and the PD1/PDL1 blocker (BMS-1) via a thioketal bond. LTB can encapsulate the photosensitizer Chlorin e6 (Ce6), constructing a co-delivery photodynamic nanoplatfform through self-assembly (LTB-6 NPs).Formule :C53H59Cl2N3O7S2Couleur et forme :SolidMasse moléculaire :985.09D5B
D5B is an effective and selective PD-L1 inhibitor that has been modified with DBCO. It degrades PD-L1 in 4T1 and B16-F10 tumor cells with EC50 values of 5.4 μM and 6.2 μM, respectively. D5B can block the PD-L1/PD-1 interaction and exhibits antitumor activity.Formule :C58H66N2O12Couleur et forme :SolidMasse moléculaire :983.15Lon-TK
Lon-TK is a glycolysis inhibitor of LTB, linked with a linker conjugate. LTB is an intelligent responsive prodrug, comprised of Lonidamine (Lon) and a PD-L1 inhibitor (BMS-1), which are connected through a thioketal linkage. It effectively inhibits glycolytic metabolism in tumor cells and blocks the PD-1/PD-L1 immune escape pathway. Lon-TK holds potential for use in photodynamic-enhanced immunotherapy research.Formule :C24H28Cl2N2O3S2Couleur et forme :SolidMasse moléculaire :527.53PD-1/PD-L1-IN-32
PD-1/PD-L1-IN-32 (compound A56) is a potent inhibitor of PD-1/PD-L1, displaying pronounced anticancer activity with an IC50 value of 2.4 nM.Degré de pureté :98%Couleur et forme :Odour SolidPD-1/PD-L1-IN-31
PD-1/PD-L1-IN-31 is a potent inhibitor of PD-1/PD-L1 (IC50=2.2 nM) that enhances IFN-γ secretion and activates the immune response of peripheral bloodFormule :C24H24ClFN2O3Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :442.91(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysis-resistant D-peptide antagonist and a potent PD-1/PD-L1 inhibitor, exhibiting an affinity for PD-1 of 0.51 μM and demonstratingFormule :C72H99F3N20O23Degré de pureté :98%Couleur et forme :SolidMasse moléculaire :1669.67LP23
LP23, a non-arylmethylamine PD-1/PD-L1 inhibitor (IC 50: 16.7 nM), exhibits anti-tumor activity through the restoration of immune cell function in HepG2/JurkatFormule :C27H27N3O5SDegré de pureté :98%Couleur et forme :SolidMasse moléculaire :505.59IMMH 010 maleate
CAS :IMMH 010 maleate (YPD-30 maleate) is a programmed cell death ligand 1 inhibitor used in the study of neurological disorders and advanced malignant solid tumors.Formule :C36H36BrClN2O9Couleur et forme :SoildMasse moléculaire :756.04PD-L1 inhibitory peptide
CAS :PD-L1inhibitory peptide is an inhibitor peptide that targets the programmed cell death ligand 1 (PD-L1). By binding to PD-L1, it lifts immune suppression and restores the anti-tumor activity of T cells. PD-L1inhibitory peptide holds promise for use in tumor research.Formule :C96H135N21O23SCouleur et forme :SolidMasse moléculaire :1983.29Human PD-L1 inhibitor IV
CAS :PD-L1 inhibitor IV, a polypeptide, competitively blocks hPD-1 with a Kd of 1.38 μM, preventing hPD-1/hPD-L1 interaction.Formule :C80H113N25O27Couleur et forme :SolidMasse moléculaire :1856.932
